Correction for: Amplification of MDMX (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity (American Society for Microbiology (2004) 24:13 (5835–5843) DOI: 10.1128/MCB.24.13.5835-5843.2004);Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity

Molecular and Cellular Biology

Volumn 24, Issue 13, 2004, Pages 5835-5843

  Danovi, Davide ^a   Meulmeester, Erik ^b   Pasini, Diego ^a   Migliorini, Domenico ^a   Capra, Maria ^a,c   Frenk, Ruth ^b   De Graaf, Petra ^b   Francoz, Sarah ^d,e   Gasparini, Patrizia ^a,c   Gobbi, Alberto ^a,c   Helin, Kristian ^a,c   Pelicci, Pier Giuseppe ^a,c   Jochemsen, Aart G ^b   Marine, Jean Christophe ^a,e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; PROTEIN MDMX; PROTEIN P53; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; EMBRYO; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; MDMX GENE; MOUSE; NONHUMAN; ONCOGENE H RAS; ORTHOLOGY; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 2942738959     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00150-19     Document Type: Erratum

References (45)

1. Barlev, N. A., L. Liu, N. H. Chehab, K. Mansfield, K. G. Harris, T. D. Halazonetis, and S. L. Berger. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8:1243-1254.
2. Bottger, V., A., Bottger, C., Garcia-Echeverria, Y. F., Ramos, A. J. van der Eb, A. G. Jochemsen, and D. P. Lane. 1999. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18:189-199.
3. Boyd, S. D., K. Y. Tsai, and T. Jacks. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563-568.
4. Brummelkamp, T. R., R. Bernards, and R. Agami. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
5. Colombo, E., J. C. Marine, D. Danovi, B. Falini, and P. G. Pelicci. 2002. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol. 4:529-533.
6. De Graaf, P., N. A. Little, Y. F. Ramos, E. Meulmeester, S. J. Letteboer, and A. G. Jochemsen. 2003. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J. Biol. Chem. 278:38315-38324.
7. el-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
8. Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8:57-69.
9. Finch, R. A., D. B. Donoviel, D. Potter, M. Shi, A. Fan, D. D. Freed, C. Y. Wang, B. P. Zambrowicz, R. Ramirez-Solis, A. T. Sands, and N. Zhang. 2002. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 62:3221-3225.
10. Freedman, D. A., C. B. Epstein, J. C. Roth, and A. J. Levine. 1997. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 3:248-259.
11. Geyer, R. K., Z. K. Yu, and C. G. Maki. 2000. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:569-573.
12. Grossman, S. R. 2001. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268:2773-2778.
13. Gu, J., H. Kawai, L. Nie, H. Kitao, D. Wiederschain, A. G. Jochemsen, J. Parant, G. Lozano, and Z. M. Yuan. 2002. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277:19251-19254.
14. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-506.
15. Harvey, M., A. T. Sands, R. S. Weiss, M. E. Hegi, R. W. Wiseman, P. Pantazis, B. C. Giovanella, M. A. Tainsky, A. Bradley, and L. A. Donehower. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467.
16. Hicks, G. G., S. E. Egan, A. H. Greenberg, and M. Mowat. 1991. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol. Cell. Biol. 11:1344-1352.
17. Ito, A., Y., Kawaguchi, C. H., Lai, J. J., Kovacs, Y., Higashimoto, E., Appella, T. P., Yao. 2002. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21:6236-6245.
18. Kalkhoven, E., H. Teunissen, A. Houweling, C. P. Verrijzer, and A. Zantema. 2002. The PHD-type zinc finger is an integral part of the CBP acetyltransferase domain. Mol. Cell. Biol. 22:1961-1970.
19. Kamijo, T., F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649-659.
20. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
21. Lin, H. J., V. Eviner, G. C. Prendergast, and E. White. 1995. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol. 15:4536-4544.
22. Liu, G., T. Xia, and X. Chen. 2003. The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J. Biol. Chem. 278:17557-17565.
23. Meulmeester, E., R. Frenk, R. Stad, P. de Graaf, J. C. Marine, K. H. Vousden, and A. G. Jochemsen. 2003. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol. 23:4929-4938.
24. Migliorini, D., D. Danovi, E. Colombo, R. Carbone, P. G. Pelicci, and J. C. Marine. 2002. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. J. Biol. Chem. 277:7318-7323.
25. Migliorini, D., E. L. Denchi, D. Danovi, A. Jochemsen, M. Capillo, A. Gobbi, K. Helin, P. G. Pelicci, and J. C. Marine. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22:5527-5538.
26. Momand, J., H. H. Wu, and G. Dasgupta. 2000. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15-29.
27. Nakamura, S., J. A. Roth, and T. Mukhopadhyay. 2000. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell. Biol. 20:9391-9398.
28. Parant, J., A. Chavez-Reyes, N. A. Little, W. Yan, V. Reinke, A. G. Jochemsen, and G. Lozano. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat. Genet. 29:92-95.
29. Prives, C., and J. L. Manley. 2001. Why is p53 acetylated? Cell 107:815-818.
30. Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
31. Rallapalli, R., G. Strachan, B. Cho, W. E. Mercer, and D. J. Hall. 1999. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem. 274:8299-8308.
32. Ramos, Y. F., R. Stad, J. Attema, L. T. Peltenburg, A. J. van der Eb, and A. G. Jochemsen. 2001. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res. 61:1839-1842.
33. Ried, T., K. E. Just, H. Holtgreve-Grez, S. du Manoir, M. R. Speicher, E. Schrock, C. Latham, H. Blegen, A. Zetterberg, T. Cremer, et al. 1995. Comparative genomic hybridization of formalin-fixed, paraffin-embedded breast tumors reveals different patterns of chromosomal gains and losses in fibroadenomas and diploid and aneuploid carcinomas. Cancer Res. 55:5415-5423.
34. Riemenschneider, M. J., C. B. Knobbe, and G. Reifenberger. 2003. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int. J. Cancer 104:752-757.
35. Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554-564.
36. Sabbatini, P., and F. McCormick. 2002. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 21:519-525.
37. Sage, J., G. J. Mulligan, L. D. Attardi, A. Miller, S. Chen, B. Williams, E. Theodorou, and T. Jacks. 2000. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14:3037-3050.
38. Sakaguchi, K., J. E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C. W. Anderson, and E. Appella. 1998. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12:2831-2841.
39. Sherr, C. J., and R. A. DePinho. 2000. Cellular senescence: mitotic clock or culture shock? Cell 102:407-410.
40. Stad, R., N. A. Little, D. P. Xirodimas, R. Frenk, A. J. van der Eb, D. P. Lane, M. K. Saville, and A. G. Jochemsen. 2001. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO Rep. 2:1029-1034.
41. Tao, W., and A. J. Levine. 1999. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96:3077-3080.
42. Tirkkonen, M., M. Tanner, R. Karhu, A. Kallioniemi, J. Isola, and O. P. Kallioniemi. 1998. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177-184.
43. Vousden, K. H., and X. Lu. 2002. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2:594-604.
44. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
45. Zindy, F., D. E. Quelle, M. F. Roussel, and C. J. Sherr. 1997. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15:203-211.